Skip to main content
. 2017 Jul 25;8(55):93502–93515. doi: 10.18632/oncotarget.19548

Figure 1. SLC40A1 and Nrf2 expression in cisplatin-sensitive ovarian cancer cells and cisplatin-resistant ovarian cancer cells.

Figure 1

(A) The mRNA expressions of Nrf2 and SLC40A1 in cisplatin-sensitive ovarian cancer cells (blue bar) and their derived cisplatin-resistant ovarian cancer cells (red bar) were determined by qRT-PCR. (B) Western blot was employed to detect the protein expression of Nrf2 and SLC40A1 in A2780 and its derived A2780CP ovarian cancer cells. (C) The protein expression of Nrf2 and SLC40A1 in COC1 and its derived COC1/DDP ovarian cancer cells were also determined through Western blot, * P<0.05, ** P<0.01.